FDA overhauls trial design with new suicide standard

The FDA has quietly engineered the biggest change-up in the way many clinical trials are designed since the early '90s. Developers working in a range of fields including obesity, epilepsy, smoking cessation, depression and more are being required to investigate the added risk of suicide. Merck, Sanofi-Aventis and Eli Lilly are all adding suicide assessments to trials, as the FDA notifies developers of the new trial standard.

The new requirement has been in the works for several years, starting with startling indications four years ago that antidepressants increased suicide risks among children and teenagers. The New York Times adds that fresh alarm bells were rung by Acomplia, an obesity drug from Sanofi-Aventis also linked to psychiatric side effects.

- read the report from The New York Times

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.